EUVIMEDEUVIMED entdecken
Crossref

Inhibition of FoxO1 ameliorates hepatic steatosis and hepatitis in nonalcoholic steatohepatitis mice through regulation of gut microbiota

Di Wen Shou, Ying Quan, Jie Min Cheng, Si Qi Yang, Jia Wei Chen, Yong Qiang Li, Chen Huang, Hui Ting Chen, Yong Jian Zhou iD

Journal of Digestive Diseases · 2024-07 · 25 (7) · 453-462

DOI: 10.1111/1751-2980.13306 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Digestive Diseases, online erschienen am 30.08.2024. Verfasst von Di Wen Shou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, Guangzhou, Guangdong Province, …. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Non-alcoholic Fatty Liver Disease, Forkhead Box Protein O1. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangzhou Municipal Science and Technology Project, Science and Technology Planning Project of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We aimed to investigate the role of forkhead box O1 (FoxO1) inhibitor AS1842856 (AS) in nonalcoholic steatohepatitis (NASH) mice and the potential mechanisms.

Methods

Mice were given methionine‐choline‐sufficient (MCS), or methionine‐ and choline‐deficient (MCD) diet for 5 weeks, along with AS (60 mg/kg) or vehicle gavage treatment (0.2 mL/day). Body and liver weight, serum triglyceride (TG), low‐density lipoprotein‐cholesterol (LDL‐C), high‐density lipoprotein‐cholesterol (HDL‐C), alanine aminotransferase (ALT), aspartate aminotransferase (AST), fasting glucose and insulin levels were measured. Liver macrophage infiltration and ileal ZO‐1 protein expression were also detected. Interleukin (IL)‐6, IL‐1β, and tumor necrosis factor (TNF)‐α, sterol regulatory element binding protein (SREBP)‐1c, phosphoenolpyruvate carboxykinase (PEPCK), and glucose‐6‐phosphatase (G6Pase), α‐smooth muscle actin (SMA), recombinant collagen type III α1 (Col3a1), and connective tissue growth factor (Ctgf) expressions were measured. Stool samples were collected for 16S rDNA sequencing.

Results

Compared to the MCD group, AS attenuated liver weight, reduced serum TG, ALT, and AST levels, increased HDL‐C levels, mitigated hepatic steatosis, decreased macrophage infiltration, and augmented ileal ZO‐1 proteins in NASH mice. It also reduced the levels of IL‐6, IL‐1β, and TNF‐α, alongside with the Srebp‐1c mRNA expression. However, no significant effects on Pepck, G6Pase, α‐SMA, Col3a1, or Ctgf were observed. Furthermore, AS promoted diversity and altered gut microbiota composition in NASH mice, causing increased beneficial bacteria like Akkermansia muciniphila , Parabacteroides distasonis , and Prevotellamassilia , which were associated with metabolic functions.

Conclusion

FoxO1 inhibitor AS ameliorated hepatic steatosis, inflammation, and intestinal dysbiosis in NASH mice, making it a potentially promising treatment for NASH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeNon-alcoholic Fatty Liver DiseaseForkhead Box Protein O1AnimalsMiceMaleLiverMice, Inbred C57BLDisease Models, AnimalHepatitis

Stichwörter der Autor:innen

forkhead box protein O1gastrointestinal microbiomehepatitisnon‐alcoholic fatty liver disease

Substanzen

Forkhead Box Protein O1Foxo1 protein, mouse

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, Guangzhou, Guangdong Province, China.
  • Department of Gastroenterology and Hepatology, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong Province, China.

ORCID-Profile: Yong Jian Zhou

Förderung

  • National Natural Science Foundation of China
  • Guangzhou Municipal Science and Technology Project
  • Science and Technology Planning Project of Guangdong Province

Zitieren

APA

Shou, D. W., Quan, Y., Cheng, J. M., Yang, S. Q., Chen, J. W., Li, Y. Q., Huang, C., Chen, H. T., & Zhou, Y. J. (2024). Inhibition of FoxO1 ameliorates hepatic steatosis and hepatitis in nonalcoholic steatohepatitis mice through regulation of gut microbiota. Journal of Digestive Diseases, 25(7), 453-462. https://doi.org/10.1111/1751-2980.13306

Vancouver

Shou DW, Quan Y, Cheng JM, Yang SQ, Chen JW, Li YQ, et al. Inhibition of FoxO1 ameliorates hepatic steatosis and hepatitis in nonalcoholic steatohepatitis mice through regulation of gut microbiota. Journal of Digestive Diseases. 2024;25(7):453-462. doi:10.1111/1751-2980.13306

BibTeX
@article{Shou2024,
  author = {Shou, Di Wen and Quan, Ying and Cheng, Jie Min and Yang, Si Qi and Chen, Jia Wei and Li, Yong Qiang and Huang, Chen and Chen, Hui Ting and Zhou, Yong Jian},
  title = {Inhibition of FoxO1 ameliorates hepatic steatosis and hepatitis in nonalcoholic steatohepatitis mice through regulation of gut microbiota},
  journal = {Journal of Digestive Diseases},
  year = {2024},
  volume = {25},
  number = {7},
  pages = {453--462},
  doi = {10.1111/1751-2980.13306}
}
Kostenlos starten →